| Company Name: | XOMA Ltd. Bermuda | | Ticker Symbol: | XOMA | | | WWW Address: | www.xoma.com | | CEO: | Steven B. Engle | | No. of Employees: | 335 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, which is engaged in the discovery, development and manufacture of therapeutic antibodies and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 0.73 |  0.0 | 0.7 | 1.02 | 0.73 | 0.73 | 0.70 | 863324 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 145.2 | 198.9 | 1.76 | -0.34 | 0.00 | 12.2 | 0.0 | 1.34 - 0.37 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 0.73 | $ | | PE Ratio - LTM | 12.2 | |
| Market Capitalisation | 145.2 | mil |
| Latest Shares Outstanding | 198.9 | mil |
| Earnings pS (EPS) | -0.34 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 202,946 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 164.3 | mil |
| Float as % of Shares Outstanding | 99.8 | % |
| Foreign Sales | 12 | mil |
| Domestic Sales | 56 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 21.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 56.60 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 29.8 | % |
| Pre-Tax Profit Margin | 11.8 | % |
| Assets Turnover | 1.9 | % |
| Return on Assets (ROA) | 13.9 | % |
| Return on Equity (ROE) | 70.1 | % |
| Return on Capital Invested (ROCI) | 31.6 | % |
| Current Ratio | 1.3 | |
| Leverage Ratio (Assets/Equity) | 5.1 | |
| Interest Cover | 2.9 | |
| Total Debt/Equity (Gearing Ratio) | 1.22 | |
| LT Debt/Total Capital | 55.0 | % |
| Working Capital pS | 0.03 | $ |
| Cash pS | 0.14 | $ |
| Book-Value pS | 0.05 | $ |
| Tangible Book-Value pS | 0.05 | $ |
| Cash Flow pS | 0.08 | $ |
| Free Cash Flow pS | 0.07 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 13.48 | |
| Price/Tangible Book Ratio | 13.48 | |
| Price/Cash Flow | 8.8 | |
| Price/Free Cash Flow | 10.9 | |
| P/E as % of Industry Group | 54.0 | % |
| P/E as % of Sector Segment | 9.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -1.2 | 97 | 16,974 | 20,426 |
| 4 Weeks | 0.81 | 0.65 | 0.68 | 7.4 | 101 | 19,171 | 325,903 |
| 13 Weeks | 1.07 | 0.65 | 0.86 | -15.1 | 79 | 37,291 | 2,274,765 |
| 26 Weeks | 1.34 | 0.65 | 0.81 | -9.9 | 75 | 42,503 | 5,312,876 |
| 52 Weeks | 1.34 | 0.37 | 0.94 | -22.3 | 63 | 27,993 | 6,970,309 |
| YTD | 1.34 | 0.37 | - | 17.7 | 96 | 30,011 | 6,812,494 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 0.76 | 0.73 | 0.77 | 0.82 | 0.73 | 1.76 | 1.68 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 83.98 | 85.0 | 46.05 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 32.69 | NA | 17.76 |
| R&D | 9.87 | NA | 12.90 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 53.1 | 229.4 | -19.3 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.40 | 0.16 | -0.24 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 17.44 |
| Current Ratio | 1.4 |
| Quick Ratio (Acid Test) | 1.0 |
| Liquidity Ratio (Cash) | 0.75 |
| Receivables Turnover | 4.7 |
| Average Collection Period | 77 |
| Working Capital/Equity | -37.3 |
| Working Capital pS | 0.08 |
| Cash-Flow pS | -0.26 |
| Free Cash-Flow pS | -0.29 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -0.72 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 146.7 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 224.6 |
| LT Debt/Total Liabilities | 64.2 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 19.05 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 7.65 |
| Tobin's Q Ratio | 2.16 |
| Current P/E Ratio - LTM | 12.20 |
| Enterprise Value (EV)/EBITDA | -7.30 |
| Enterprise Value (EV)/Free Cash Flow | -4.70 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 13.48 |
| Price/Book Ratio - LTM | 13.48 |
| Price/Cash Flow Ratio | 8.8 |
| Price/Free Cash Flow Ratio - LTM | 10.9 |
| Price/Sales Ratio | 1.29 |
| P/E Ratio (1 month ago) - LTM | 12.8 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 54.0 |
| P/E as % of Sector Segment | 9.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 8.2 |
| PER SHARE FIGURES |
| LT Debt pS | 0.45 |
| Current Liabilities pS | 0.19 |
| Tangible Book Value pS - LTM | 0.05 |
| Book Value pS - LTM | 0.05 |
| Capital Invested pS | 0.16 |
| Cash pS - LTM | 0.14 |
| Cash Flow pS - LTM | 0.08 |
| Free Cash Flow pS - LTM | 0.07 |
| Earnings pS (EPS) | -0.34 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -60.36 |
| Free Cash Flow Margin 5YEAR AVG | -353.14 |
| Net Profit Margin | -66.5 |
| Net Profit Margin - 5YEAR AVRG. | -90.9 |
| Equity Productivity | -2.17 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 2.13 |
| Return on Capital Invested (ROCI) | -142.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -117.6 |
| Assets Productivity | 0.90 |
| Return on Assets (ROA) | -67.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | -51.2 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 29.8 |
| EBIT Margin - LTM | 17.9 |
| Pre-Tax Profit Margin | -67.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -91.1 |
| Effective Tax Rate | 0.8 |
| Effective Tax Rate - 5YEAR AVRG. | 0.2 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 88 |
| Revenue per Employee | 202,946 |
| Net Income per Employee | -135,060 |
| Average Collection Period | 88 |
| Receivables Turnover | 4.7 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 14.67 |
| Assets/Revenue | 1.11 |
| Net Working Capital Turnover | 5.80 |
| Fixed Assets Turnover | 2.39 |
| Total Assets Turnover | 0.9 |
| Revenue per $ Cash | 7.15 |
| Revenue per $ Plant | 2.53 |
| Revenue per $ Common Equity | -2.17 |
| Revenue per $ Capital Invested | 2.13 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 35.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 53.7 |
| Research & Devlopment (R&D) as % of Revenue | 121.5 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 121.5 |
|
|  
|
| |
 |  |